GH Research PLC
GHRSNasdaq
$28.71
↓ -1.4%Jul 17 close · end-of-day
Price
1Y↑ +66.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD)
- CEO
- Theis Terwey
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Website
- ghres.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 16, 2026
Jul 2, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.